Two phase Ib clinical trials revealed that a combination of savolitinib and osimertinib or gefitinib showed promising antitumor activity and tolerable toxicity in patients with acquired MET-amplified NSCLC [21, 22]. Here, MET is linked to non-small cell lung carcinoma.